Semaglutide is a medication used in this clinical trial to help heal foot ulcers in patients with type 2 diabetes. It works by mimicking a hormone in the body that helps control blood sugar levels. By doing so, it may improve blood flow and promote healing in areas like foot ulcers, which are common complications in people with diabetes. This trial aims to see if semaglutide can effectively aid in the healing process of these ulcers compared to not using it.

Type 2 Diabetes – Type 2 diabetes is a chronic condition that affects the way the body processes blood sugar (glucose). It is characterized by insulin resistance, where the body’s cells do not respond properly to insulin, and eventually, the pancreas may not produce enough insulin. Over time, high blood sugar levels can lead to various complications, including damage to the eyes, kidneys, nerves, and heart. The disease often develops gradually and may initially present with symptoms such as increased thirst, frequent urination, and fatigue. As the condition progresses, individuals may experience more severe complications if blood sugar levels are not managed effectively. Lifestyle factors, such as diet and physical activity, play a significant role in the development and progression of type 2 diabetes.

Diabetic Foot Ulcer – A diabetic foot ulcer is an open sore or wound that occurs on the foot of a person with diabetes. It is a common complication of diabetes, resulting from a combination of factors such as poor circulation, nerve damage (neuropathy), and high blood sugar levels. The ulcer typically develops on the bottom of the foot and can become infected if not properly cared for. As the ulcer progresses, it may lead to tissue damage and, in severe cases, affect deeper structures like tendons and bones. The healing process can be slow, especially if blood sugar levels are not well-controlled. Preventive care and regular monitoring are crucial to managing and reducing the risk of diabetic foot ulcers.